Authors

Vuong Thi Ngoc Lan, M.D., Ho Manh Tuong, M.D., Ha Tan Duc, M.D., Phung Huy Tuan, M.D., Huynh Gia Bao, M.D., Peter Humaidan, D.M.Sc.

Volume 105, Issue 2, Pages 356-363

Abstract

Objective:

To determine the optimal GnRH agonist dose for triggering of oocyte maturation in oocyte donors.

Design:

Single-center, randomized, parallel, investigator-blinded trial.

Setting:

IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.

Patient(s):

One hundred sixty-five oocyte donors (aged 18–35 years, body mass index [BMI] <28 kg/m2, antimüllerian hormone level >1.25 ng/mL, and antral follicle count ≥6).

Intervention(s):

Ovulation trigger with 0.2, 0.3, or 0.4 mg triptorelin in a GnRH antagonist cycle.

Main Outcome Measure(s):

The primary end point was number of metaphase II oocytes. Secondary end points were fertilization and cleavage rates, number of embryos and top-quality embryos, steroid levels, ovarian volume, and ongoing pregnancy rate (PR) in recipients.

Result(s):

There were no significant differences between the triptorelin 0.2, 0.3, and 0.4 mg trigger groups with respect to number of metaphase II (16.0 ± 8.5, 15.9 ± 7.8, and 14.7 ± 8.4, respectively), embryos (13.2 ± 7.8, 11.7 ± 6.9, 11.8 ± 7.0), and number of top-quality embryos (3.8 ± 2.9, 3.6 ± 3.0, 4.1 ± 3.0). Luteinizing hormone levels at 24 hours and 36 hours after trigger was significantly higher with triptorelin 0.4 mg versus 0.2 mg and 0.3 mg (9.8 ± 7.1 IU/L vs. 7.3 ± 4.1 IU/L and 7.2 ± 3.7 IU/L, respectively; 4.6 ± 3.2 IU/L vs. 3.2 ± 2.3 IU/L and 3.3 ± 2.1 IU/L, respectively. Progesterone level at oocyte pick-up +6 days was significantly higher in the 0.4-mg group (2.2 ± 3.7 IU/L) versus 0.2 mg (1.1 ± 1.0 IU/L) and 0.3 mg (1.2 ± 1.6 IU/L). One patient developed early-onset severe ovarian hyperstimulation syndrome (OHSS).

Conclusion(s):

No significant differences between triptorelin doses of 0.2, 0.3, and 0.4 mg used for ovulation trigger in oocyte donors were seen with regard to the number of mature oocytes and top-quality embryos.

Clinical Trial Registration Number:

NCT02208986.

Read the full text at: http://www.fertstert.org/article/S0015-0282(15)02021-X/fulltext